| Index | — | P/E | 10.38 | EPS (ttm) | 0.78 | Insider Own | — | Shs Outstand | 845.97M | Perf Week | 7.14% |
| Market Cap | 6.85B | Forward P/E | 6.58 | EPS next Y | 1.23 | Insider Trans | — | Shs Float | 834.63M | Perf Month | 10.96% |
| Enterprise Value | 15.84B | PEG | 0.52 | EPS next Q | 0.36 | Short Float | 0.84% | Perf Quarter | 3.05% | ||
| Income | 527.00M | P/S | 0.79 | EPS this Y | 20.94% | Short Ratio | 12.15 | Perf Half Y | -1.58% | ||
| Sales | 8.67B | P/B | 0.75 | EPS next Y | 25.87% | ROA | 2.25% | Short Interest | 6.99M | Perf YTD | -13.37% |
| Book/sh | 10.77 | P/C | 11.34 | EPS next 5Y | 20.06% | ROE | 8.43% | 52W High | 9.90 -18.18% | Perf Year | -13.74% |
| Cash/sh | 0.71 | P/FCF | 8.17 | EPS past 3/5Y | 25.41% -5.03% | ROIC | 5.47% | 52W Low | 6.96 16.38% | Perf 3Y | 4.38% |
| Dividend Est. | 0.11 (1.31%) | EV/EBITDA | 7.76 | Sales past 3/5Y | 8.53% 6.01% | Gross Margin | 37.23% | Volatility | 3.39% 2.38% | Perf 5Y | -41.13% |
| Dividend TTM | 0.11 (1.31%) | EV/Sales | 1.83 | EPS Y/Y TTM | 64.38% | Oper. Margin | 16.66% | ATR (14) | 0.21 | Perf 10Y | -46.22% |
| Dividend Ex-Date | Jul 02, 2026 | Quick Ratio | 0.81 | Sales Y/Y TTM | 7.04% | Profit Margin | 6.09% | RSI (14) | 66.77 | Recom | 2.75 |
| Dividend Gr. 3/5Y | — 4.19% | Current Ratio | 2.37 | EPS Q/Q | 32.21% | SMA20 | 6.42% | Beta | 0.76 | Target Price | — |
| Payout | 28.31% | Debt/Eq | 1.05 | Sales Q/Q | 1.63% | SMA50 | 6.70% | Rel Volume | 1.49 | Prev Close | 8.04 |
| Employees | 25,258 | LT Debt/Eq | 1.01 | Earnings | Nov 02 | SMA200 | 1.27% | Avg Volume | 538.33K | Price | 8.10 |
| IPO Date | Jun 02, 2011 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.45% -3.11% | Net Debt/EBITDA | 4.40 | Volume | 803,382 | Change | 0.75% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-12-24 | Downgrade | Deutsche Bank | Hold → Sell | |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold | |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform | |
| Mar-11-21 | Upgrade | HSBC | Hold → Buy | |
| Oct-28-19 | Upgrade | Santander | Hold → Buy | |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight | |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold | |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy | |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal Weight → Underweight | |
| Dec-02-15 | Downgrade | HSBC | Buy → Hold |
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8,668 | 8,153 | 7,803 | 7,130 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 5,440 | 5,243 | 4,780 | 4,444 | — | — | — | — | — | |
| Gross Profit | 3,227 | 2,911 | 3,023 | 2,686 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,308 | 1,152 | 1,238 | 1,369 | — | — | — | — | — | |
| Research and Development | 478 | 404 | 415 | 428 | — | — | — | — | — | |
| Other Operating Expense | -3 | 15 | 81 | 43 | — | — | — | — | — | |
| Operating Income | 1,443 | 1,339 | 1,290 | 846 | — | — | — | — | — | |
| Interest Expense | 625 | 677 | 836 | 558 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -38 | 4 | 27 | -64 | — | — | — | — | — | |
| Net Income Before Taxes | 780 | 666 | 480 | 224 | — | — | — | — | — | |
| Income Taxes | 150 | 125 | 250 | 47 | — | — | — | — | — | |
| Consolidated Net Income | 527 | 436 | 170 | 46 | — | — | — | — | — | |
| Net Income From Continuing Operations | 631 | 542 | 230 | 177 | — | — | — | — | — | |
| Net Income | 527 | 436 | 170 | 46 | — | — | — | — | — | |
| EPS (Recurring) | 0.78 | 0.64 | 0.25 | 0.10 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.78 | 0.64 | 0.25 | 0.10 | — | — | — | — | — | |
| EPS (Diluted) | 0.78 | 0.64 | 0.25 | 0.10 | — | — | — | — | — | |
| EBITDA | 2,040 | 1,831 | 1,606 | 1,265 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.38 | 14.54 | 29.90 | 118.75 | — | — | — | — | — | |
| Price To Sales Ratio | 0.64 | 0.78 | 0.65 | 1.10 | — | — | — | — | — | |
| Gross Margin | 37.23 | 35.70 | 38.74 | 37.67 | — | — | — | — | — | |
| Operating Margin | 16.65 | 16.42 | 16.53 | 11.87 | — | — | — | — | — | |
| Net Margin | 6.08 | 5.35 | 2.18 | 0.65 | — | — | — | — | — | |
| Shares Outstanding | 681 | 681 | 680 | 680 | — | — | — | — | — | |
| Market Capitalization | 5,516 | 6,367 | 5,059 | 7,861 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |